Fibromyalgia Drug Patent Application Filed by Premier Biomedical

Fibromyalgia Drug Patent Application Filed by Premier Biomedical
El Paso, Texas-based Premier Biomedical Inc. announced it has filed a provisional patent application on a second drug, in addition to Feldetrex, for the treatment of fibromyalgia (FM), alcohol and chemical addiction, multiple sclerosis (MS) symptoms and neuropathic pain. Established in 2010, Premier Biomedical is a biotechnology research company dedicated to the discovery, development, and commercialization of medical treatments for a broad spectrum of diseases – including novel therapies for muscular dystrophy, atherosclerosis, neurofibromatosis and breast cancer. Premier Biomedical has made license agreements to obtain the technology behind numerous provisional patents in the U.S. and a PCT Europe National Patent, and has set partnerships with the Department of Defense Center of Expertise at the William Beaumont Army Medical Center. Premier's Feldetrex’s submission to the U.S. Food and Drug Administration (FDA) for the treatment of fibromyalgia was announced in 2015. Feldetrex is a drug combination intended to treat the symptoms affecting fibromyalgia patients, including anxiety and fatigue, sleeping disturbances, morning stiffness, painful tender points and chronic muscle pain. In last year's announcement, Premier’s chairman of the Scientific Advisory Board, Mitchell S. Felder, M.D., said, “We are very excited about this drug’s ability to relieve the symptoms of fibromyalgia without many of the negative side effects associated with many of the current drug treatments.” With no additional details, a recent 
Subscribe or to access all post and page content.